Article

Nivolumab for unresectable cutaneous epithelial malignancies: An open-label, single-arm, multi-centre, phase II trial (NMSC-PD1)

2026-02-04

Abstract excerpt

<title>Abstract</title> <p>Background Data in East Asian patients and in other epithelial skin cancers, including extramammary Paget’s disease (EMPD) and adnexal carcinomas, are scarce. Therefore, we conducted a phase II trial of nivolumab in Japanese patients with advanced non-melanoma skin cancers (NMSCs). Patients and methods: This multicentre, open-label, single-arm phase II study enrolled adults (≥ 20 year...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 41aa8fde-94dc-54cb-b516-7a92c12bc27c
DOI: 10.21203/rs.3.rs-8709454/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Nivolumab for unresectable cutaneous epithelial malignancies: An open-label, single-arm, multi-centre, phase II trial (NMSC-PD1)DOI 10.21203/rs.3.rs-8709454/v1Read

FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma.Semantic proximity Read

Nivolumab in Previously Untreated Melanoma without BRAF MutationSemantic proximity Read

Front-line Chemo-immunotherapy with Nivolumab and Dose-Adjusted (DA) EPOCH in Peripheral T-cell Lymphoma: A Phase I TrialSemantic proximity Read

Nivolumab plus ipilimumab for elderly Chinese patients with advanced non-small cell lung cancerSemantic proximity Read

Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trialSemantic proximity Read

Melanoma patient response to nivolumab treatment for metastatic lung lesions: Multi-OMICS analysis in Project HOPE.Semantic proximity Read

Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma.Semantic proximity Read

Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan.Semantic proximity Read

Association Between Genetic Variants and the Risk of Nivolumab-Induced Immune-Related Adverse EventsSemantic proximity Read

Anti-PD-1 antibodies in metastatic uveal melanoma: a treatment option?Semantic proximity Read

Pembrolizumab in advanced acral lentiginous melanoma: final results of a single-centre, open-label, phase II trial in an East Asian populationSemantic proximity Read

Safety and Efficacy of Intratumoral Anti-CTLA4 with Intravenous Anti-PD1Semantic proximity Read